- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Intellia Therapeutics Inc (0JBU)"Intellia Therapeutics Inc stock price live, this page displays NASDAQ NTLA stock exchange data. View the NTLA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Intellia Therapeutics Inc real time stock price chart below.
What Is the Intellia Therapeutics Inc Stock Price Today?
The Intellia Therapeutics Inc stock price today is 13.79.
What Is the Stock Symbol for Intellia Therapeutics Inc?
The stock symbol for Intellia Therapeutics Inc is ""NTLA.""
What Stock Exchange Does Intellia Therapeutics Inc Trade On?
Intellia Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Intellia Therapeutics Inc a Good Stock to Buy?
Determining whether Intellia Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NTLA quote. (ISIN: US45826J1051)"
What Is the Intellia Therapeutics Inc Stock Price Today?
The Intellia Therapeutics Inc stock price today is 13.79.
What Is the Stock Symbol for Intellia Therapeutics Inc?
The stock symbol for Intellia Therapeutics Inc is ""NTLA.""
What Stock Exchange Does Intellia Therapeutics Inc Trade On?
Intellia Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Intellia Therapeutics Inc a Good Stock to Buy?
Determining whether Intellia Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NTLA quote. (ISIN: US45826J1051)"
13.79
0.00(0.00%)
Real-time Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.59
14.50
52 wk Range
13.00
28.09
0JBU Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.5914.50
52 wk Range
13.0028.09
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
Unlock0JBU Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
59.78
Upside
+337.95%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
13 analysts have revised their earnings upwards for the upcoming period
- Is Trump 2.0 good or bad for healthcare stocks?
- Investing.com
Pro
- Is Trump 2.0 good or bad for healthcare stocks?
- Investing.com
Pro
Intellia Therapeutics Inc Company Profile
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Compare 0JBU to Peers and Sector
Metrics to compare | 0JBU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship0JBUPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.7x | −1.8x | −0.7x | |
PEG Ratio | 1.67 | −0.01 | 0.00 | |
Price/Book | 1.4x | 2.3x | 2.6x | |
Price / LTM Sales | 32.3x | 5.9x | 3.2x | |
Upside (Analyst Target) | - | 343.1% | 44.1% | |
Fair Value Upside | Unlock | 28.6% | 8.2% | Unlock |
FAQ
What Is the Intellia Therapeutics Inc (0JBU) Stock Price Today?
The Intellia Therapeutics Inc stock price today is 13.79
What Stock Exchange Does Intellia Therapeutics Inc Trade On?
Intellia Therapeutics Inc is listed and trades on the London stock exchange.
What Is the Stock Symbol for Intellia Therapeutics Inc?
The stock symbol for Intellia Therapeutics Inc is "0JBU."
What Is the Intellia Therapeutics Inc Market Cap?
As of today, Intellia Therapeutics Inc market cap is 1.39B.
What is Intellia Therapeutics Inc Earnings Per Share?
The Intellia Therapeutics Inc EPS is -5.44.
What Is the Next Intellia Therapeutics Inc Earnings Date?
Intellia Therapeutics Inc will release its next earnings report on 19 Feb 2025.
From a Technical Analysis Perspective, Is 0JBU a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.